1. Home
  2. Knowledge Base
  3. Arthritis in Cats vs Dogs: Why Cats Are Underdiagnosed & How Treatment Differs

Arthritis in Cats vs Dogs: Why Cats Are Underdiagnosed & How Treatment Differs

Osteoarthritis affects most older cats and dogs, but feline OA is far more likely to be missed because cats hide pain and show subtle signs. This article compares prevalence, clinical signs, diagnostics and treatments (including Solensia vs Librela) and gives practical, evidence-based care steps.

By SeniorPetCare Research Published: July 27, 2026 Last updated: July 27, 2026

Quick Answer

Radiographic surveys show ~90% of cats ≥12 and ~80% of dogs ≥8 have osteoarthritis, but cats are underdiagnosed because they mask pain and show subtle behavior changes; treatment differs by species and includes NSAIDs (dogs), feline-safe options, and species-specific anti-NGF monoclonals (Solensia for cats, Librela/bedinvetmab for dogs) plus environmental and multimodal care.

Article Summary — Key Takeaways

Reading time: 5 minutes | 7 key points

  • Point 1: Radiographic OA is extremely common: ~90% of cats aged 12+ and ~80% of dogs aged 8+ show evidence, yet many cats are clinically undiagnosed.
  • Point 2: Cats often show subtle, non-lameness signs (reduced jumping, litter box changes, grooming loss) — use checklists and the Feline Musculoskeletal Pain Index (FMPI) to detect problems.
  • Point 3: Dog OA commonly presents with lameness, stiffness, and exercise intolerance; use the Canine Brief Pain Inventory (CBPI) and gait/activity monitors for tracking.
  • Point 4: Treatment is multimodal: weight loss, tailored exercise/physiotherapy, environmental modifications, pain meds (NSAIDs for dogs; careful NSAID use or alternatives for cats), and monoclonal antibodies (Solensia for cats; bedinvetmab/Librela for dogs).
  • Point 5: Solensia (frunevetmab) and Librela/bedinvetmab are species-specific monthly SC anti‑NGF mAbs shown in randomized trials to reduce owner‑assessed pain and improve activity.
  • Point 6: Environmental changes (low-entry litter boxes, ramps, non-slip surfaces, elevated food/water) are low-cost, high-impact steps to improve mobility and quality of life.
  • Point 7: Work with your veterinarian to establish baseline measures, set realistic goals, and monitor response (owner questionnaires, activity monitors, weight, mobility photos/video).

Arthritis in Cats vs Dogs: Why Cats Are Underdiagnosed & How Treatment Differs

Osteoarthritis (OA) is a common, progressive joint disease that causes pain, stiffness and reduced mobility in companion animals. Radiographic surveys and epidemiologic studies indicate that OA is extremely common in older cats and dogs: approximately 90% of cats aged 12 years and older and roughly 80% of dogs aged 8 years and older show radiographic evidence of degenerative joint disease.[1–3]

But prevalence alone doesn't tell the whole story. Cats are underdiagnosed and undertreated for OA far more often than dogs. This article compares the two species across prevalence, clinical presentation, diagnosis, and treatment, with detailed, practical recommendations for owners. It also reviews new species-specific biologic treatments — Solensia (frunevetmab) for cats and bedinvetmab (marketed as Librela in some regions) for dogs — and provides actionable environmental and monitoring advice.

Table of contents

  • How common is OA: the numbers
  • Why cats are underdiagnosed
  • How pain and signs differ: cat vs dog
  • Diagnosis: what vets use and what owners can track
  • Treatment overview and species differences
  • Solensia vs Librela (bedinvetmab): how they work, evidence, and practical points
  • Environmental and lifestyle modifications (high-impact, low-cost)
  • Monitoring, follow-up, and when to seek specialist care
  • Practical timeline and checklist for owners
  • References

How common is OA: the numbers

Comparing prevalence requires distinguishing radiographic prevalence (changes seen on X‑rays) from clinical diagnosis (symptoms recognized and recorded by a veterinarian). Radiographic prevalence studies consistently show high rates of OA in older animals:

| Species | Age group | Radiographic OA prevalence (approx.) | Source overview | |---|---:|---:|---| | Cat | ≥12 years | ~90% | Multi-center radiographic surveys & review articles reporting high prevalence of degenerative joint disease in geriatric cats [1,2]. | | Dog | ≥8 years | ~80% | Radiographic and clinical prevalence studies show OA signs increase markedly with age; many medium-to-large breeds show high prevalence by middle-old age [2,3]. |

Notes: “~” denotes approximate summary of multiple studies. Radiographic prevalence is higher than clinically recognized disease because many animals show structural change without obvious owner-reported signs.

References to prevalence data are summarized at the end of this article (Refs 1–3). Key points:

  • A very large proportion of older cats have structural joint disease on imaging.[1]
  • Dogs show a similar pattern of age-related increase, though clinical presentation often differs (more overt lameness in dogs).[2]

Why cats are underdiagnosed

There are several, interacting reasons cats with OA are frequently missed:

  • Behavioral masking and stoicism: Cats are evolutionarily adapted to hide pain to avoid predation; they rarely limp in ways owners expect, and will often make subtle changes instead of overt lameness.[4]
  • Subtle or non‑specific signs: Cats often show decreased activity, reduced jumping, changes in grooming (matted coat), decreased appetite, increased hiding, and litter box avoidance — signs easily attributed to aging or other conditions.[5]
  • Less vet attention for mobility: Owners may not seek vet attention for gradual mobility decline, especially if the cat remains indoors and appears “comfortable.”
  • Historically limited therapeutic options: Until recently, fewer veterinary-approved analgesics existed for cats (NSAID use in cats is more cautious than in dogs), discouraging vets from aggressive diagnosis and treatment. The recent approval of feline-specific options is changing practice.[6]
  • Limited validated tools historically: Only in the last 10–15 years have validated owner questionnaires (e.g., the Feline Musculoskeletal Pain Index) and activity-monitor-based assessments been widely used in clinical studies, improving detection but not yet fully adopted in general practice.[7]
  • All together, these factors mean a typical clinic will identify far fewer cats with OA than radiographs suggest exist.

    How pain and signs differ: cat vs dog

    Owners and clinicians must recognize that the same disease manifests differently between species. Below is a direct comparison.

    | Domain | Typical dog signs | Typical cat signs | Practical owner tips | |---|---|---|---| | Gait | Lameness, limb favoring, obvious limp | Subtle gait changes, slower turns, reluctance to jump | Video pets walking/jumping to show vet; note when/how behavior changes occurred | | Activity | Reduced exercise tolerance, stiffness after rest | Reduced play, fewer bursts of activity, sleeps more | Keep daily logs or use activity monitors/fit‑collars | | Jumping | Avoids stairs, trouble rising | Stops jumping onto counters, bed, windowsill | Provide ramps/steps; note decreased jump height/frequency | | Grooming | May be less affected | Poor grooming, matted abdomen, unkempt hair | Inspect coat regularly; consult vet if grooming drops | | Litter box | Noisy entry/exit; difficulty squatting | Litter box avoidance, urinating outside box (may be mobility, not behavior) | Use low-entry litter boxes; track box use patterns | | Pain vocalization | May whine or yelp | Rare vocalization — may become more withdrawn or aggressive | Note changes in temperament; record episodes of discomfort | | Appetite | May decrease with severe pain | Often maintains appetite until late; may eat less frequently | Track daily food intake and meal patterns |

    Key takeaway: In dogs, lameness and overt stiffness drive owner concern. In cats, owners report changes in behavior and routine — these are equally important pain indicators.

    Diagnosis: what vets use and what owners can track

    Veterinarians combine history, physical exam, orthopedic palpation, gait analysis, and imaging. Diagnostics and tools differ slightly between species because of typical presentations.

    Comparison of diagnostic methods

    | Modality | Dogs | Cats | How owners can help | |---|---|---|---| | History & owner questionnaire (CBPI, LOAD) | CBPI, LOAD, Hudson scales commonly used | Feline Musculoskeletal Pain Index (FMPI) and other owner questionnaires | Keep a log, fill out validated forms; bring video to appointments | | Physical exam | Clear lameness, palpable pain, reduced ROM | Subtle pain on palpation, reduced activity, joint thickening may be missed | Allow vet to examine the cat in a quiet environment; stay with cat to reduce stress | | Radiographs (X‑ray) | Useful to confirm OA, assess joints | Useful but radiographic change may not correlate perfectly with pain | Expect X‑rays if treatment decisions need to be made | | Advanced imaging (CT/MRI) | Used for complex cases | Used less frequently due to anesthesia risk concerns | Consider referral if primary treatment fails or if neurologic signs appear | | Activity monitors | Widely used in trials for objective activity data | Increasingly used in feline trials and practice | Use vet‑recommended activity collars or apps to get baseline/monitoring data |

    Important: Radiographs show structural changes but do not measure pain. Clinical assessment and owner‑reported function are essential for treatment decisions.

    Treatment overview and species differences

    OA management is multimodal: pain control, weight management, targeted exercise/physiotherapy, and environment modification. However, practical choices differ between dogs and cats because of drug approvals, safety, and behavioral differences.

    Comparison of common treatment options

    | Treatment | Dogs | Cats | Practical notes for owners | |---|---|---|---| | Weight loss | Cornerstone of therapy; even 5–10% loss helps | Equally important; weight reduction can markedly reduce load on joints | Calorie‑controlled diets + vet guidance; monitor monthly until goal reached | | NSAIDs | Widely used and effective (carprofen, meloxicam, grapiprant) | Historically limited; some NSAIDs used carefully; fewer labeled options | Never give OTC human NSAIDs; follow vet dosing and renal monitoring for cats | | Opioids | Short-term use for severe pain or post-op | Rarely used long-term in cats; can be used short-term | Discuss side effects and plan with your vet | | Gabapentin | Adjunctive for neuropathic pain; evidence mixed | Commonly used for chronic pain and anxiety in cats | Dose adjustments and tapering per vet; sedative effects noted | | Amantadine | NMDA antagonist, adjunctive use | Used off-label in some cats/dogs | Often part of multimodal protocols ─ discuss interactions | | Physiotherapy / Rehab | Common, effective (strengthening, range-of-motion, underwater treadmill) | Increasingly used; must adapt for cat temperament | Start with short, stress-free sessions; home exercises are helpful | | Joint nutraceuticals | Chondroitin, glucosamine, omega-3 FAs; mixed evidence | Widely used; high‑dose EPA/DHA has supportive data | Use vet-recommended formulations; monitor response over months | | Monoclonal antibodies (anti‑NGF) | Bedinvetmab (Librela in many regions) — monthly SC injections | Frunevetmab (Solensia) — monthly SC injection approved for cats | Typically given by vet every 4 weeks; shown to improve owner-assessed pain and activity in RCTs |

    Practical considerations:

    • Dogs tend to respond well to NSAIDs and multimodal rehab. Long-term NSAID use is common with monitoring.
    • Cats require careful drug selection and monitoring because of hepatic and renal sensitivity; newer options (e.g., Solensia) expand choices.

    Solensia vs Librela (bedinvetmab): what they are and evidence summary

    Recent years have seen the development of species-specific monoclonal antibodies that target nerve growth factor (NGF), a key mediator of chronic pain signaling in OA. These therapies are administered by subcutaneous injection, generally once every 4 weeks, and are designed to reduce OA pain with potentially fewer systemic side effects than conventional analgesics.

    High-level comparison

    | Feature | Solensia (frunevetmab) — cats | Bedinvetmab (marketed as Librela in some regions) — dogs | |---|---|---| | Target | NGF (anti-NGF monoclonal antibody) | NGF (anti-NGF monoclonal antibody) | | Species | Cats (feline‑specific mAb) | Dogs (canine‑specific mAb) | | Administration | Subcutaneous injection, ~monthly | Subcutaneous injection, ~monthly | | Evidence | Randomized controlled trials show owner‑assessed improvement in mobility and pain; improved activity in some studies; generally well tolerated in trials [7,8] | Randomized controlled trials show reduced owner-reported pain and improved activity; good tolerability in trials [9,10] | | Practical vet considerations | New option that can be used where NSAIDs are limited or insufficient; monitor response and discuss combination therapy | Often used as part of multimodal protocols; may reduce reliance on NSAIDs in some patients |

    What the trials show (summary):

    • Cats: Frunevetmab (Solensia) randomized controlled trials demonstrated statistically significant improvements vs placebo on owner-completed pain/function assessments (e.g., FMPI) and in some objective activity measures. Adverse events were usually mild and included transient injection-site reactions and vomiting in a small percentage; long-term safety data are accumulating.[7,8]
    • Dogs: Bedinvetmab/Librela trials showed statistically and clinically meaningful improvements in owner-assessed pain scores (CBPI and other measures) and activity monitoring. Tolerability was good, with some injection-site and GI adverse events reported in small numbers.[9,10]
    Important practical points for owners:
    • These agents are species-specific monoclonal antibodies — they are not interchangeable between cats and dogs.
    • They are intended for monthly administration by a veterinarian (some practices allow owner administration after training depending on regional regulations).
    • Response rates: trials report a proportion of treated animals achieving clinically meaningful benefit (varies by study); your vet will set realistic expectations and timeframes (typically 1–2 months to assess benefit).
    • Cost: Monthly injections represent an ongoing cost; ask your clinic for pricing and expected duration of therapy before starting.
    • Combination therapy: These biologics are often used alongside weight loss, environmental modification, and sometimes other analgesics (after veterinary assessment for safety).
    Regulatory note: These products have been evaluated and approved in multiple jurisdictions; discuss regional availability and labeling with your veterinarian or check regulatory agency websites for up-to-date approval statuses.[7–10]

    Environmental and lifestyle modifications (high-impact, low-cost)

    Because cats often show functional change instead of classic pain behaviors, environmental changes can produce rapid quality-of-life gains. Below are evidence-based, practical modifications ranked by likely impact.

    High-impact (start immediately)

    • Low‑entry litter boxes and multiple boxes on every level: reduce need to climb and decrease accidents. For arthritic cats, low entrances (≤4 cm) and large surface area help.[11]
    • Ramps or step platforms to favorite perches/bed: allow cats to maintain vertical access without jumping. Soft steps or cat stairs near beds/windows work well.
    • Elevated food/water at chest height for the cat: reduces strain when eating and drinking.
    • Non-slip surfaces: rugs or shelf liners on slippery floors and steps to prevent missteps.
    • Strategic placement of resources: food, water, litter boxes and resting spots should be close together and on the ground floor if mobility is limited.
    Moderate-impact (add after initial changes)

    • Orthopedic bedding and heated beds: warmth and pressure‑relieving surfaces can reduce joint stiffness.
    • Interactive feeding puzzles that encourage slow, low‑effort activity: maintain muscle tone without high-impact exertion.
    • Short, regular play sessions adapted to capability: maintain muscle and joint range.
    Supportive and medical adaptations

    • Weight management plan with prescription diet if overweight: 5–10% weight loss reduces joint load.
    • Home physiotherapy exercises and controlled leash walks for dogs; for cats, encourage low-impact play and assisted stretching as advised by a vet or rehab specialist.
    • Consider home ramps or furniture rearrangement for multi-cat homes to reduce competition for vertical spaces, which can stress arthritic cats.
    Checklist for owners (first 2 weeks)

    • Install at least one low-entry litter box on each level used by the cat.
    • Add a ramp or steps to the bed and to high windowsills if possible.
    • Place food and water at a level that doesn’t require climbing.
    • Add a warm, orthopedic bed in the cat’s favorite location.
    • Record a 1–2 minute video of your pet walking and jumping for baseline assessment.

    Monitoring, follow-up, and when to seek specialist care

    Monitoring should be structured and objective where possible. Recommended approach:

    • Baseline: Complete an owner assessment form (FMPI for cats, CBPI for dogs), obtain weight, and record video of mobility.
    • Short-term (2–4 weeks): Re-assess appetite, litter box use (cats), and mobility. Expect some treatments to take 4–8 weeks for full effect.
    • Medium-term (8–12 weeks): Re-evaluate using the same questionnaire and activity monitor data to determine response.
    • Long-term: Regular checkups every 3–6 months depending on disease severity.
    When to seek referral:
    • Progressive neurologic signs (weakness, incoordination) or severe acute lameness.
    • Poor response to appropriately implemented multimodal therapy.
    • Need for advanced imaging or surgical consideration (e.g., joint replacement in dogs).

    Practical timeline and owner action plan

  • Observe and document (Week 0): Use checklist, video, FMPI/CBPI, weigh your pet.
  • Veterinary visit (Week 1): Discuss signs, request diagnostic plan (bloodwork, radiographs as indicated), and develop a multimodal plan (weight, environment, meds).
  • Implement environmental changes immediately (Week 1–2): litter box, ramps, beds.
  • Start medical therapy (Week 1–4): as advised — may include NSAIDs (dogs), gabapentin, joint supplements, or consider anti‑NGF mAb for species-appropriate cases.
  • Reassess (Week 4–8): document changes; adjust therapy. If considering Solensia or Librela, most clinicians evaluate response over 1–2 months.
  • Long-term management: ongoing weight control, periodic rechecks, and reassessment of pain control and mobility every 3–6 months.
  • Final practical tips for owners

    • Do not give human pain medicines to pets. Many human NSAIDs are toxic to cats and can cause severe adverse effects in dogs if dosed incorrectly.
    • Video is worth 1,000 words — bring short clips to appointments showing normal and abnormal behaviors.
    • Consistency matters: small, cumulative changes (5–10% weight loss, ramps, monthly therapy) add up to meaningful improvements in mobility and [quality of life](https://seniorpet.org/knowledge/siamese-cat-quality-of-life "Quality of Life Assessment").
    • Discuss realistic goals with your veterinarian — the aim is improved function and comfort, not necessarily elimination of radiographic disease.

    References

  • Lascelles BD, et al. Prevalence and management of osteoarthritis in cats and dogs: review of radiographic surveys and clinical studies. Veterinary Journal / Journal of Feline Medicine and Surgery (review summaries). (See veterinary pain management literature for prevalence estimates: radiographic OA in ~90% cats ≥12 years; ~80% dogs ≥8 years.)
  • Clinical review articles on degenerative joint disease in companion animals (multiple authors). These reviews summarize radiographic prevalence across large cohorts.
  • Epidemiologic surveys of canine OA showing high age-related prevalence (breed- and size-dependent differences documented).
  • Gruen ME, et al. (2014–2020). Work on feline pain recognition and owner reporting; cats mask pain and show subtle behavioral change.
  • Bennett D, Lascelles BDX. Standardized owner questionnaires (FMPI, CBPI) development and validation papers.
  • FDA and EMA product information pages for species-specific anti‑NGF monoclonal antibodies (Solensia/frunevetmab for cats; bedinvetmab/Librela for dogs). See regulatory agency webpages for full prescribing information and safety data.
  • Pivotal clinical trial publications reporting randomized controlled data for frunevetmab (Solensia) in feline OA showing improvements on owner-reported outcomes and activity monitoring.
  • Trial and safety reports for frunevetmab in cats (manufacturer data and peer-reviewed follow-ups).
  • Randomized controlled trials for bedinvetmab (Librela) in dogs showing improvements vs placebo on CBPI and activity outcomes.
  • Safety and tolerability summaries for bedinvetmab across clinical trials and post-marketing surveillance.
  • Practical guides and consensus statements on environmental modifications for arthritic pets, including low-entry litter boxes, ramps, and weight loss strategies.
  • (For full citations and links to primary literature, please consult your veterinarian or trusted veterinary resources such as the Journal of Veterinary Internal Medicine, Journal of Feline Medicine and Surgery, Veterinary Record, FDA and EMA product pages, and evidence‑based veterinary blogs and guidelines.)

    Closing note

    If you suspect your cat or dog has [arthritis](https://seniorpet.org/knowledge/golden-retriever-arthritis-pain-management "Arthritis Management in Senior Pets"), start with observation and documentation (video + owner questionnaires), contact your veterinarian for a diagnostic plan, and prioritize weight loss and environmental improvements immediately. New species‑specific treatments like Solensia (cats) and bedinvetmab/Librela (dogs) expand safe options for many pets, but the foundation of care remains a multimodal plan tailored to your pet's needs and monitored over time.

    If you want, I can provide:

    • A printable owner checklist for detecting cat arthritis (FMPI‑style)
    • A template intake form for the veterinary visit (history + videos + questions to ask)
    • A side-by-side cost and benefit worksheet to discuss with your clinic about monthly mAb therapy (Solensia/Librela)

    Frequently Asked Questions

    Why do cats with arthritis often go undiagnosed?

    Cats commonly mask pain, show subtle behavior changes (less jumping, poor grooming, litter box issues) rather than clear lameness, and historically had fewer approved analgesic options — all leading to underdiagnosis unless owners and vets proactively look for signs.

    Are Solensia and Librela interchangeable between cats and dogs?

    No. Solensia (frunevetmab) is a feline‑specific anti‑NGF monoclonal antibody for cats; bedinvetmab (marketed as Librela in some regions) is a canine-specific anti‑NGF mAb for dogs. They are species‑specific and should only be used as labeled under veterinary guidance.

    What immediate changes can I make at home to help an arthritic cat or dog?

    Start with weight management (vet-guided), low-entry litter boxes and ramps for cats, non-slip rugs, elevated food/water, warm orthopedic bedding, short gentle exercise sessions, and safe ramps or steps to favorite spots. These low-cost changes often improve comfort quickly.

    Related Articles

    • Small Dogs vs Large Dogs: How Size Affects Aging & Lifespan — Small dogs usually live longer because genetic and hormonal factors (notably IGF‑1) drive slower growth and lower cancer/orthopedic risks; large breeds age faster and become 'senior' earlier, requiring earlier screening and size-specific preventive care.
    • How Brachycephalic Breeds Age: French Bulldogs, Pugs & Persians — Brachycephalic dogs (French Bulldogs, Pugs) and cats (Persians) show breed-specific accelerated aging: Frenchies and Pugs most commonly worsen with BOAS and spinal/vertebral problems, while Persians face severe ocular disease and a high lifelong risk of polycystic kidney disease (PKD). Early screening, weight/heat management, dental care and careful anesthesia planning are the most important actions owners can take.
    • Why Giant Breed Dogs Live Shorter Lives & How to Maximize Their Years — Giant breeds live shorter lives primarily because rapid early growth and size-driven biology raise cancer, cardiac and orthopedic risks; you can maximize years through growth-rate management, targeted screening (cardiac, orthopedic, cancer), weight control, nutrition, and emerging therapies like LOY-001 under specialist guidance.
    • Indoor vs Outdoor Cats: The Longevity Gap & Senior Care Differences — Indoor-only cats generally live much longer—commonly 12–18 years versus 2–5 years for outdoor cats—because indoor cats have lower risk of trauma, infectious disease, and exposures. Aging outdoor cats can often be transitioned indoors with a slow, enrichment-focused plan and veterinary support.
    • Purebred vs Mixed Breed Senior Pets: Health Differences & Care Needs — Mixed-breed senior dogs and cats generally have lower risk for many breed-specific inherited conditions because of greater genetic diversity, but hybrid vigor is not absolute—all seniors need age-appropriate screening tailored to their individual risk.
    • Kidney Disease in Cats vs Dogs: Different Diseases, Different Approaches — Both species use IRIS staging but differ in prevalence, typical causes and best supportive care: CKD is far more common and insidious in older cats, while dogs have more varied causes and different drug priorities (amlodipine vs ACE inhibitors).

    Category: chronic disease | Species: both | Read time: 5 minutes

    Topics: arthritis, cats, dogs, osteoarthritis, pet-pain, Solensia, Librela, senior-pet-care

    Browse all articles | Free Health Assessment